Aura Biosciences, Inc. (AURA): Price and Financial Metrics
GET POWR RATINGS... FREE!
AURA Stock Price Chart Interactive Chart >
AURA Price/Volume Stats
| Current price | $17.01 | 52-week high | $26.16 |
| Prev. close | $16.48 | 52-week low | $13.50 |
| Day low | $16.26 | Volume | 57,000 |
| Day high | $17.27 | Avg. volume | 36,492 |
| 50-day MA | $18.48 | Dividend yield | N/A |
| 200-day MA | $0.00 | Market Cap | 497.71M |
Aura Biosciences, Inc. (AURA) Company Bio
Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform to treat tumors of high unmet need in ocular and urologic oncology. Its AU-011, a VDC candidate, is being developed for the first line treatment of primary choroidal melanoma, a rare disease with no drugs approved. The company also develops AU-011 in additional ocular oncology indications, including choroidal metastases. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Cambridge, Massachusetts.
Latest AURA News From Around the Web
Below are the latest news stories about Aura Biosciences Inc that investors may wish to consider to help them evaluate AURA as an investment opportunity.
Aura Biosciences to Present Preclinical Data Demonstrating Applicability of AU-011 in Bladder Cancer at the 2022 ASCO Genitourinary Cancer SymposiumCAMBRIDGE, Mass., February 14, 2022--Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced the presentation of preclinical data for its first VDC product candidate, AU-011, which is being developed for the treatment of Non-Muscle Invasive Bladder Cancer (NMIBC). The results will be presented as part of the 2022 American Society of Clinical Oncology (ASCO |
Aura Biosciences to Participate at the 11th Annual SVB Leerink Global Healthcare ConferenceCAMBRIDGE, Mass., February 09, 2022--Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced that Elisabet de los Pinos, PhD, Chief Executive Officer of Aura, will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare conference taking place on Wednesday, February 16, 2022, at 8:40 a.m. Eastern Time. |
Medicxi Ventures Management (Jersey) Ltd Buys Aura Biosciences IncInvestment company Medicxi Ventures Management (Jersey) Ltd (Current Portfolio) buys Aura Biosciences Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Medicxi Ventures Management (Jersey) Ltd. |
What Percentage Of Aura Biosciences, Inc. (NASDAQ:AURA) Shares Do Insiders Own?The big shareholder groups in Aura Biosciences, Inc. ( NASDAQ:AURA ) have power over the company. Institutions often... |
Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK) and Aura Biosciences Inc (AURA)There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Merck & Company (MRK – Research Report) and Aura Biosciences Inc (AURA – Research Report) with bullish sentiments. Merck & Company (MRK) Leerink Partners analyst Daina Graybosch maintained a Buy rating on Merck & Company yesterday and set a price target of $102.00. The company's shares closed last Monday at $74.89. According to TipRanks. |
AURA Price Returns
| 1-mo | 0.29% |
| 3-mo | -4.97% |
| 6-mo | -2.47% |
| 1-year | N/A |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 0.18% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...